Final ID in part. Specifically, the Commission determined to review the following issues: (1) The Final ID’s finding that the accused products satisfy the limitation “a second mode of operation comprising the low voltage event” of claims 1, 6, and 12 of the ‘985 patent; (2) the Final ID’s finding that the accused turbines having a doubly-fed induction generator (“DFIG”) satisfy the limitation “turbine controller causes the blade pitch control system to vary the pitch of the one or more blades” of claims 1, 6, and 12 of the ‘985 patent; (3) the Final ID’s finding that certain full-converter turbines with later versions of software and DFIG Products infringe claims 29, 30, 33–35, and 37 of the ’985 patent; and (4) the Final ID’s finding that the accused products satisfy the limitation “during the entire duration of and subsequent to a zero voltage fault that lasts for an undetermined period of time” of claim 1 of the ’705 patent. The Commission also determined to take no position on whether GE showed that the accused products satisfy the limitation “during the entire duration of and subsequent to a zero voltage fault that lasts for an undetermined period of time.” and therefore affirmed the Final ID’s finding of no violation as to claim 1 of the ’705 patent based on 35 U.S.C. 101. The Commission did not review any other findings presented in the final ID.

The Commission sought briefing from the parties on six issues and requested briefing from the parties, interested persons, government agencies, and interested public. On December 7, 2021, GE and SGRE filed their initial submissions in response to the Commission’s request for briefing. On December 14, 2021, GE and SGRE filed their reply submissions in response to the Commission’s request for briefing. The Commission also received submissions from U.S. Representative Paul Tonko; U.S. Representative William Timmons; Senator Patrick Leahy; Senator Tim Scott; Senators John Hoeven, Kevin Cramer, and Kelly Ayotte; Senators Charles Grassley and Joni Ernst; Governor Kim Reynolds of Iowa; Governor Laura Kelly of Kansas; RWE Renewables Americas, LLC; Enel Green Power North America, Inc.; Avangrid Renewables, LLC; Allete Clean Energy; Clearway Energy Group, LLC; Algonquin Power & Utilities Corp.; and MidAmerican Energy Company.

Having examined the record of this investigation, including the Final ID, the petitions for review, responses, and other submissions from the parties and the public, the Commission has determined that GE failed to show any accused SGRE products satisfies the limitation “a second mode of operation comprising the low voltage event” found in claims 1, 6, and 12 of the ’985 patent. The Commission has further determined that GE failed to show that the accused SGRE DFIG products satisfy the limitation “turbine controller causes the blade pitch control system to vary the pitch of the one or more blades” of claims 1, 6, and 12 of the ’985 patent. Finally, the Commission finds that GE showed that the accused full-converter wind turbine generators with earlier versions of software infringe claims 29, 30, 33–35, and 37 of the ’985 patent, but that GE did not show that the accused DFIG wind turbines generators or the accused full-converter wind turbine generators with later versions of software infringed those claims. The Commission therefore reverses the Final ID’s finding that SGRE infringes claims 1, 6, and 12 of the ’985 patent, but finds that GE showed infringement of claims 29, 30, 33–35, and 37 of the ’985 patent by the accused full-converter wind turbine generators with earlier versions of software. Accordingly, the Commission finds that GE has shown a violation of section 337 by SGRE with respect to claims 29, 30, 33–35, and 37 of the ’985 patent.

The Commission’s determinations are explained more fully in the accompanying Opinion. All other findings in the ID under review that are consistent with the Commission’s determinations are affirmed.

The Commission has further determined that the appropriate form of relief in this investigation is a limited exclusion order with respect to SGRE prohibiting the importation of certain variable speed wind turbine generators and components thereof that are covered by one or more of claims 29, 30, 33–35, and 37 of the ’985 patent, and cease and desist orders that prohibits SGRE from further importing, selling, and distributing those products in the United States. The Commission has further determined that the public interest factors enumerated in subsection 337(d)(1) and (f)(1) (19 U.S.C. 1337(d)(1) and (f)(1)) warrant an exemption in both orders for the service and repair of subject articles that were sold to U.S. consumers as of the date of the orders, but do not otherwise prejudice the issuance of the limited exclusion order or the cease and desist orders. Finally, the Commission has determined that the bond for importation during the period of Presidential review shall be in the amount of zero percent (0%) (i.e., no bond) of the entered value of such articles.

The Commission’s notice, order, and opinion were delivered to the President and to the United States Trade Representative on the day of their issuance. The Commission has also notified the Secretary of the Treasury and Customs and Border Protection of the order. The investigation is hereby terminated.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: January 18, 2022.

Lisa Barton, Secretary to the Commission.

[FR Doc. 2022–01234 Filed 1–21–22; 8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–875]

Importer of Controlled Substances Application: Globyz Pharma, LLC; Correction

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application; correction.

SUMMARY: The Drug Enforcement Administration (DEA) published a document in the Federal Register on August 12, 2021, concerning a notice of application. The document indicated the approved drug code (1205—Lisdexamfetamine) as a schedule I. The correct drug schedule should read schedule II.

SUPPLEMENTARY INFORMATION: Correction

In the Federal Register of August 12, 2021, in FR Doc. 2021–17181 (86 FR 44405), on page 44406, in the first column, in the controlled substance table, correct the drug schedule to schedule II.

Brian S. Besser,
Acting Assistant Administrator.

[FR Doc. 2022–00852 Filed 1–21–22; 8:45 am]